# QNRX (Quoin Pharmaceuticals, Ltd.) - SEC EDGAR Financial Statements

> Quoin Pharmaceuticals, Ltd. reported $34.75M in total assets and a net loss of $19.59M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/QNRX
- Markdown: https://convexityos.com/fundamentals/QNRX.md
- SEC CIK: 0001671502
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:08 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001671502&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$16.29M | Operating profit |
| Net Income | FY 2025 | -$19.59M | GAAP bottom line |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $33.18M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | $0 | $0 | $0 |
| Research & Development | $9.80M | $3.60M | $3.31M | $2.67M | $1.56M | $244K | $46K |
| Selling, General & Admin | $6.49M | $5.93M | $6.07M | $6.58M | $4.50M | $1.43M | $1.51M |
| **Operating Income** | -$16.29M | -$9.53M | -- | -- | -- | -- | -- |
| Interest Income | $482K | $558K | -- | $96K | -- | -- | -- |
| Interest Expense | -- | -- | -- | -- | $1.09M | $47K | -- |
| Income Before Tax | -$15.80M | -$8.96M | -- | -- | -- | -- | -- |
| **Net Income** | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -$21.46M | -$2.10M | -$1.56M |
| Basic EPS | -- | -- | -- | -- | -$0.00 | -$0.03 | -$0.02 |
| **Diluted EPS** | -- | -- | -- | -- | -$0.00 | -$0.03 | -$0.02 |
| Basic Shares Outstanding | -- | -- | -- | -- | 33.08B | 25.08B | 25.08B |
| Diluted Shares Outstanding | -- | -- | -- | -- | 33.08B | 25.08B | 25.08B |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $2.66M | $3.63M | $3.43M | $3.10M | $2.28M | $2.05M | $2.37M | $1.05M |
| Selling, General & Admin | $2.27M | $1.85M | $1.70M | $1.42M | $1.74M | $1.74M | $1.58M | $1.35M |
| Interest Income | $125K | $101K | $147K | $172K | $62K | $103K | $145K | -- |
| **Net Income** | -$4.87M | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -$3.81M | -$2.31M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.82M | $3.62M | $2.40M | $2.86M | $7.48M | $324K |
| Short-Term Investments | $14.93M | $10.43M | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $18.75M | $14.06M | $2.40M | $2.86M | $7.48M | $324K |
| **Total Current Assets** | $20.01M | $14.93M | $11.29M | $13.37M | $8.20M | $465K |
| Intangible Assets | $383K | $483K | $583K | $705K | $809K | $913K |
| **Total Non-Current Assets** | $383K | $783K | $883K | $1.09M | $1.16M | $913K |
| **Total Assets** | $20.39M | $15.71M | $12.17M | $14.46M | $9.36M | $1.38M |
| Accounts Payable | $1.26M | $906K | $527K | $606K | $923K | -- |
| Other Current Liabilities | $600K | $600K | $600K | $600K | -- | -- |
| **Total Current Liabilities** | $5.55M | $4.18M | $3.58M | $3.53M | $4.58M | -- |
| Other Non-Current Liabilities | $1.72M | $2.32M | $2.92M | $3.52M | -- | -- |
| **Total Non-Current Liabilities** | $1.72M | $2.32M | $2.92M | $3.52M | $4.12M | -- |
| **Total Liabilities** | $7.27M | $6.50M | $6.51M | $7.05M | $8.70M | $7.99M |
| Common Stock | $0 | $0 | $0 | $0 | -- | -- |
| Retained Earnings | -$70.97M | -$55.17M | -$46.20M | -$37.52M | -$28.07M | -$6.61M |
| Accumulated Other Comp. Income | -$613 | $55.20M | $46.20M | $37.50M | $28.10M | -- |
| **Total Stockholders' Equity** | $13.12M | $9.20M | $5.66M | $7.41M | $657K | -$6.61M |
| Total Equity | $13.12M | $9.20M | $5.66M | $7.41M | $657K | -$6.61M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $10.10M | $3.85M | $3.12M | $3.82M | $1.83M | $1.67M | $3.82M | $3.62M |
| Short-Term Investments | $23.08M | $6.95M | $10.92M | $14.93M | -- | -- | -- | $10.43M |
| **Cash & Short-Term Investments** | $33.18M | $10.80M | $14.04M | $18.75M | $1.83M | $1.67M | $3.82M | $14.06M |
| **Total Current Assets** | $34.40M | $11.64M | $15.33M | $20.01M | $6.02M | $8.48M | $12.50M | $14.93M |
| Intangible Assets | $308K | $333K | $358K | $383K | $408K | $433K | $458K | $483K |
| **Total Non-Current Assets** | $347K | $333K | $358K | $383K | $408K | $433K | $458K | $783K |
| **Total Assets** | $34.75M | $11.97M | $15.69M | $20.39M | $6.42M | $8.91M | $12.96M | $15.71M |
| Accounts Payable | $1.58M | $3.11M | $1.78M | $1.26M | $1.86M | $874K | $644K | $906K |
| Other Current Liabilities | $600K | $600K | $600K | $600K | $600K | $600K | $600K | $600K |
| **Total Current Liabilities** | $4.78M | $6.61M | $5.35M | $5.55M | $5.76M | $4.34M | $4.86M | $4.18M |
| Other Non-Current Liabilities | $1.27M | $1.42M | $1.57M | $1.72M | $1.87M | $2.02M | $2.17M | $2.32M |
| **Total Non-Current Liabilities** | $1.27M | $1.42M | $1.57M | $1.72M | $1.87M | $2.02M | $2.17M | $2.32M |
| **Total Liabilities** | $6.05M | $8.04M | $6.92M | $7.27M | $7.64M | $6.36M | $7.03M | $6.50M |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$86.21M | -$81.34M | -$75.97M | -$70.97M | -$66.62M | -$62.67M | -$58.98M | -$55.17M |
| Accumulated Other Comp. Income | $2.1K | -$582 | -$159 | -$613 | -- | $62.70M | $59.00M | $55.20M |
| **Total Stockholders' Equity** | $28.70M | $3.93M | $8.77M | $13.12M | -$1.21M | $2.55M | $5.93M | $9.20M |
| Total Equity | $28.70M | $3.93M | $8.77M | $13.12M | -$1.21M | $2.55M | $5.93M | $9.20M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -$21.46M | -$2.10M | -$1.56M |
| Stock-Based Compensation | $1.15M | $1.26M | $1.09M | $764K | $0 | -- | -- |
| **Operating Cash Flow** | -$13.54M | -$7.86M | -$7.86M | -$8.48M | -$5.72M | -$1.34M | -$1.30M |
| Purchases of Investments | -$12.26M | -$17.25M | -$18.09M | -$9.90M | -- | -- | -- |
| Sales & Maturities of Investments | $7.99M | $15.37M | $20.28M | -- | -- | -- | -- |
| **Investing Cash Flow** | -$4.28M | -$1.89M | $2.19M | -$10.15M | -$625K | -$125K | -- |
| Common Stock Issued | $18.61M | $11.57M | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $18.01M | $10.97M | $5.22M | $14.01M | $13.50M | $1.79M | $1.30M |
| **Net Change in Cash** | $195K | $1.22M | -$459K | -$4.62M | $7.16M | $324K | -$40 |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$4.87M | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -$3.81M | -$2.31M |
| Stock-Based Compensation | $484K | $533K | $445K | $283K | $182K | $321K | $360K | $326K |
| **Operating Cash Flow** | -$5.77M | -$3.14M | -$4.87M | -$5.04M | -$2.23M | -$3.69M | -$2.59M | -$2.24M |
| Purchases of Investments | -$21.09M | -$982K | -$981K | -- | -- | -- | -- | -$6.00M |
| Sales & Maturities of Investments | $5.00M | $5.00M | $5.10M | $996K | $2.54M | $1.68M | $2.77M | $2.82M |
| **Investing Cash Flow** | -$16.09M | $4.02M | $4.12M | -$11.27M | $2.54M | $1.68M | $2.77M | -$3.18M |
| **Financing Cash Flow** | $28.11M | -$152K | $56K | $18.29M | -$150K | -$150K | $23K | $5.92M |
| **Net Change in Cash** | $6.25M | $721K | -$694K | $1.99M | $162K | -$2.15M | $199K | $507K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -120.5% | -97.4% | -153.4% | -126.7% | -3266.6% | -- | -- |
| Return on Assets (ROA) | -77.5% | -57.1% | -71.4% | -64.9% | -229.4% | -152.1% | -- |
| Current Ratio | 3.61x | 3.57x | 3.15x | 3.79x | 1.79x | -- | -- |
| Quick Ratio | 3.38x | 3.36x | 0.67x | 0.81x | 1.64x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -68.3% | -474.6% | -193.7% | -120.5% | -- | -477.0% | -176.3% | -97.4% |
| Return on Assets (ROA) | -56.4% | -155.9% | -108.3% | -77.5% | -214.3% | -136.5% | -80.6% | -57.1% |
| Current Ratio | 7.20x | 1.76x | 2.87x | 3.61x | 1.04x | 1.95x | 2.57x | 3.57x |
| Quick Ratio | 6.95x | 1.63x | 2.63x | 3.38x | 0.32x | 0.38x | 0.79x | 3.36x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
